Genflow Biosciences PLC (LSE:GENF) Chief executive Dr Eric Leire tells Proactive the group has secured up to €3.375mln in non-dilutive funding. It comes in the form of a grant from the regional government of Wallonia, in southern Belgium, and was awarded to the company’s local subsidiary that will be paid in half-yearly tranches starting with €767,253.
The total cash injection will cover the costs for two years of the pre-clinical research and development programme for its AAV/SIRT6 gene therapy, which is developed to treat progeria, a form of premature ageing.